Fortress Biotech (NASDAQ:FBIO – Get Free Report) and bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.
Earnings & Valuation
This table compares Fortress Biotech and bioAffinity Technologies”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fortress Biotech | $63.26 million | 1.95 | $6.82 million | $3.17 | 1.17 |
| bioAffinity Technologies | $6.16 million | 0.56 | -$14.91 million | ($11.77) | -0.06 |
Profitability
This table compares Fortress Biotech and bioAffinity Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fortress Biotech | 193.12% | 109.66% | 45.56% |
| bioAffinity Technologies | -280.53% | -285.75% | -143.71% |
Analyst Ratings
This is a summary of current ratings and recommmendations for Fortress Biotech and bioAffinity Technologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fortress Biotech | 1 | 1 | 2 | 0 | 2.25 |
| bioAffinity Technologies | 1 | 0 | 0 | 0 | 1.00 |
Fortress Biotech presently has a consensus price target of $17.00, indicating a potential upside of 358.22%. Given Fortress Biotech’s stronger consensus rating and higher possible upside, equities analysts plainly believe Fortress Biotech is more favorable than bioAffinity Technologies.
Insider & Institutional Ownership
96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by company insiders. Comparatively, 2.7% of bioAffinity Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Risk and Volatility
Fortress Biotech has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, bioAffinity Technologies has a beta of -1.11, suggesting that its stock price is 211% less volatile than the S&P 500.
Summary
Fortress Biotech beats bioAffinity Technologies on 14 of the 14 factors compared between the two stocks.
About Fortress Biotech
Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company’s early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
About bioAffinity Technologies
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
